To determine if inactivated poliovirus vaccine combined with diphtheria and tetanus toxoids and whole-cell pertussis vaccine interferes with the immunogenicity of pertussis vaccine, we performed a randomized trial of diphtheria and tetanus toxoids and pertussis vaccine combined with inactivated poliovirus vaccine given as a single injection or as two separate injections at the same visit to infants immunized at 2, 4, and 6 months of age. A total of 84 infants were enrolled in the study; 44 received the single injection, and 40 received separate injections. Before immunization, there were no differences in antibody values between the two groups. After two vaccine doses, infants immunized with the single injection had significantly lower values of antibody to filamentous hemagglutinin (8.3 vs. 23.7 ELISA units; P < .001), fimbriae (266.5 vs. 771.8 ELISA units; P < 0.01), and the 69-kD membrane protein (442.2 vs. 1,352 ELISA units; P < .001). After the third dose, these differences persisted, and differences were also detected for antibody to pertussis toxin (10.0 vs. 35.5 ELISA units; P < .001) and a whole-bacteria antigen preparation (2,667 vs. 3,829 ELISA units; P < .05).
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We conclude that there is a diminished antibody response to the pertussis vaccine when inactivated poliovirus vaccine is combined with the diphtheria and tetanus toxoids and pertussis vaccine.
With the dramatic new developments in childhood vaccines, an increasing number of antigens have been recommended for infant immunization. Because of concerns about the number of injections given during a single visit, vaccines have been combined with the standard diphtheria and tetanus toxoids and pertussis vaccine (DTP) to allow simultaneous administration. Combination vaccines have the potential for achieving greater vaccine coverage by decreasing the number of health care visits needed to complete the immunization series and perhaps by increasing public acceptability [1] . There are potential problems with combination vaccines [2] ; a number of studies have demonstrated diminished antibody response when antigens are given in combination.
Inactivated poliovirus vaccine (IPV) has been used in combination with DTP for > 30 years in regions of Canada and in a number of European countries. Although some studies showed decreased values of antibodies to Bordetella pertussis, measurement of values of antibodies to specific B. pertussis antigens was not possible [3] [4] [5] [6] [7] . In a nonrandomized study of Canadian infants receiving DTP and oral poliovirus vaccine or DTP combined with IPV (DTP-IPV), we found a diminished antibody response to B. pertussis antigens in recipients of the vaccine containing IPV [8] . To determine if IPV combined with DTP interfered with the immunogenicity of pertussis vaccine, we performed a randomized trial of DTP combined with IPV given as a single injection (DTP-IPV) or as two separate injections (DTP + IPV).
Methods
Two licensed formulations of whole-cell pertussis vaccine were used (Connaught Laboratories, North York, Ontario, Canada). The first formulation (DTP) contained diphtheria toxoid (25 limits of flocculation), tetanus toxoid (5 limits of flocculation), pertussis vaccine (4-12 mouse protective units), aluminum phosphate (0.5 mg), and thimerosal (0.01%). The second formulation (DTP-IPV) had the same content of diphtheria toxoid, tetanus toxoid, pertussis vaccine, and aluminum phosphate adjuvant but also included poliovirus type I (Mahoney; 40 D antigen units), type 2 (MEF1; 8 D antigen units), and type 3 (Saukett; 32 D antigen units); 0.5% phenoxyethanol was used as the preservative. IPV (Connaught Laboratories) contained the same poliovirus strains and antigen concentrations as did DTP-IPV. One lot of DTP and one lot of DTP-IPV were used.
Healthy 2-month-old infants with no contraindications for pertussis immunization [9] were recruited from two primary care multiphysician practices in Dartmouth, Nova Scotia, Can-em 1996; 22 (January) ada. Infants were assigned by a computer-generated list of random numbers to receive vaccine as either separate injections (DTP + IPV) or a single injection (quadrivalent DTP-IPV).
Immunizations were given by the intramuscular route into the musculi vastus lateralis. For those infants randomized to receive DTP + IPV, IPV was administered by intramuscular injection into the musculi vastus lateralis of the opposite thigh. Serum was obtained before the first and third dose and I month after the third dose. Antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), the 69-kD membrane protein (69 kD), fimbriae 2 and 3 (FIM), and a heat-inactivated, formalininactivated whole-bacteria preparation (WB) were measured by enzyme immunoassay as previously described [8] . The WB assay measures antibody to an indeterminate and uncharacterized array of antigens contained in the whole-cell vaccine. In a previous study [10] , this assay correlated best with adverse reactions associated with the whole-cell vaccine. Geometric mean values of antibodies were compared by z-tests; proportions were compared by X 2 analysis. No adjustments were made for multiple comparisons. The protocol was approved by the local institutional review board; informed consent was obtained from the parents of all participants.
Results
A total of 99 infants were enrolled in the study; all three blood specimens from 84 infants (44 received DTP + IPV and 40 received DTP-IPV) were available for analysis. There were no differences between the two groups in birth weight or age at immunization. The mean ages of the infants at the first second, and third immunizations were 8.9 weeks (range, 7.3-11.0 weeks), 18.2 weeks (range, 15.7-24.1 weeks), and 27.4 weeks (range, 24.6-34.1 weeks), respectively. Fifty-six percent of the infants were female. There were no statistically significant differences in adverse reactions in the two groups of vaccinees (data not shown). Before immunization, there were no differences in antibody values between the two groups (table 1). A vigorous antibody response to 69 kD, FIM, and WB was elicited in both groups; a lesser, but statistically significant, antibody response to FHA was demonstrated. An antibody response to PT was demonstrated only in the DTP + IPV group. By 6 months of age, after two doses of vaccine, recipients of DTP-IPV had significantly lower values of antibody to FHA, 69 kD, and FIM than did recipients of DTP + IPV. By 1 month after the third dose, DTP-IPV recipients also had lower values of antibody to PT as well as to WB.
The proportion of infants achieving a fourfold increase in antibody value after immunization was significantly different for antibody to PT (table 2) . Recipients ofDTP-IPV were less likely to have this degree of rise in antibody value. The mean rise in antibody value after immunization was lower for antibodies to PT and FHA in the group who received the single injection than in the group who received separate injections.
Although protective antibody values have not been established for pertussis vaccines, the proportion of infants achieving arbitrary antibody values was lower in the DTP-IPV group than in the DTP + IPV group (table 2). These differences were most notable for antibodies to PT and FHA.
Discussion
The interaction of antigens in combination vaccines is receiving increasing attention as recommendations for infant immunization change with the availability of new vaccines [1] . This randomized study supports the conclusions of a previous nonrandomized study [8] that found a diminished antibody response to B. pertussis antigens when poliovirus vaccine was administered with DTP. The data are also similar to the findings of a number of earlier studies that consistently demonstrated a trend toward lower values of agglutinins to B. pertussis when IPV was combined with DTP [3] [4] [5] [6] [7] . An enhanced antibody response to DTP combined with IPV has only been reported in a single study [11] .
The nature of antigen interactions in combination vaccines is not known. DTP and DTP-IPV used in this study were produced by the same manufacturer with identical procedures for production ofthe pertussis components of each formulation. Lot-to-lot variation might contribute to the differences detected since a batch of pertussis vaccine is designated for DTP or DTP-IPV at the initiation of the manufacturing process. However, DTP and DTP-IPV must meet the same regulatory requirements (4-12 mouse protective units) so a minimum potency is guaranteed, although it is possible that in the combination process DTP-IPV lots end up at the lower end of the potency range than do DTP lots. It is unlikely that simple lot-to-lot variation can explain these consistent findings.
Factors other than the vaccine antigens may playa role in the diminished antibody response to the combination vaccine. Because thimerosal interferes with the poliovirus component, phenoxyethanol is used as a preservative for DTP-IPV, whereas DTP contains thimerosal. IPV given as a separate injection also contains phenoxyethanol. In our previous study [8] , children who were immunized with oral poliovirus vaccine rather than with IPV had an even better antibody response to B.
pertussis antigens than did the DTP + IPV recipients; this finding suggests that if phenoxyethanol is a factor then there is a spectrum of effect depending on its inclusion with the pertussis components or even its administration at the same time.
It is not known whether these differences in immunogenicity have any effect on the efficacy of the vaccine. The antibody correlates of protection are not well established for pertussis. In older studies, resistance to infection in the community correlated best with the agglutinin titer, but the presence of agglutinin antibodies did not ensure protection of a given individual [12] . Agglutinins correlate most closely with antibodies to fimbriae [13] ; in this study, although a difference was demon- strated between the two groups, high values of antibodies to fimbriae were elicited by both vaccines. These interactions become increasingly important as jurisdictions contemplate the change from oral poliovirus vaccine to IPV with the eradication of poliovirus from the Western Hemisphere [14] . In nine of 10 provinces in Canada, IPV is now routinely administered as a single injection with DTP and
Haemophilus infiuenzae type b conjugate vaccine. In the United States, the debate over the relative merits of the two programs continues, although it will be increasingly difficult to justify oral poliovirus vaccine programs with no circulation of wild poliovirus.
It is not known whether similar effects ofIPV will be demonstrated when it is combined with acellular pertussis vaccine. Currently, phase 3 trials of the efficacy of several acellular pertussis vaccines are being performed worldwide, and the results will soon be reported [15] . It is hoped that an antibody correlate of immunity will be determined during these studies. NOTE. DTP-IPV = single injection of diphtheria and tetanus toxoids and pertussis vaccine and inactivated poliovirus vaccine; DTP + IPV = two separate injections of DTP and IPV; FHA = filamentous hemagglutinin; FIM = fimbriae; 69kD = 69-kD protein; PT = pertussis toxin; WB = whole bacteria.
* Ratio of the 7-month antibody value to the lower of the 2-or 6-rnonth antibody values. pertussis antigens in these acellular vaccines may be a major factor in the decision to incorporate them into routine immunization programs.
